Table 2 Summarized RRs of overall and subgroup analysis for T1 NMIBC patients with p53 overexpression
From: p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis
Variables | No. of studies | Random effects RR (95 % CI) | Heterogeneity | Subgroup analysis P value | |
|---|---|---|---|---|---|
I 2 (%) | P value | ||||
Overall | 12 | 2.41 (1.55, 3.75) | 42 | 0.06 | <0.0001 |
Ethnicity | 0.44 | ||||
Asian | 2 | 3.09 (1.48, 6.46) | 0 | 0.003 | |
Non-Asian | 10 | 2.20 (1.41, 3.45) | 46 | 0.0005 | |
Stage | 0.63 | ||||
T1G3 | 3 | 2.71 (1.31, 5.64) | 0 | 0.007 | |
All NMIBC | 9 | 2.24 (1.40, 3.59) | 52 | 0.0008 | |
Intravesical therapy | 0.18 | ||||
Pure BCG | 5 | 3.35 (1.89, 5.93) | 0 | <0.0001 | |
Non-pure | 7 | 1.97 (1.17, 3.33) | 57 | 0.03 | |
Antibody | 0.49 | ||||
DO7 | 7 | 2.59 (1.64, 4.08) | 0 | <0.0001 | |
Pab1801 | 3 | 3.38 (1.73, 6.60) | 0 | 0.0003 | |
Others | 2 | 1.38 (0.36, 5.34) | 89 | 0.002 | |
Cutoff | 0.41 | ||||
20 % | 7 | 2.68 (1.92, 3.74) | 9 | <0.0001 | |
Others | 5 | 1.83 (0.78, 4.26) | 51 | 0.16 | |